Recent Finacing
Recent Raise
Ermium Therapeutics is a discovery-stage biotech developing orally available small molecules that modulate CXCR4 to suppress type I interferon and inflammatory cytokines for SLE, dermatomyositis, Sjögren and related interferonopathies.
